Should You Sell to a Corporate Dental Group or an Independent Buyer?
This question comes up in almost every exit conversation we have with practice owners. You have built a practice over years, perhaps decades. Now a corporate acquirer approaches you, or you start thinking about an independent sale to an associate or a smaller group. Which route gives you better value, a cleaner tax outcome, and the exit you actually want?
The honest answer is that it depends on your mix of NHS and private work, your personal tax position, how the deal is structured, and how much control you want afterwards. This article compares the two paths under the 2026/27 rules, focusing on the financial and practical differences rather than the marketing gloss. We talk in multiple ranges, not specific offers, because every contract and patient base is different.
Corporate Acquirer vs Independent Buyer: the Two Routes
Corporate acquirers are the national and regional groups that roll up practices into a larger network: the large dental bodies corporate, mid-sized consolidators, and private-equity-backed platforms. They buy practices to integrate them into a centralised support structure, retaining the existing team and standardising back-office functions, procurement and clinical systems. They can often pay a higher headline price, because they have cheaper debt, economies of scale, and a clear acquire-and-integrate strategy. Where a group specifically wants your location, scale, or private patient base, a strategic premium can push the price above the normal independent multiple ranges. The trade-off is that you usually give up operational control, and the process can be slower and more structured.
An independent sale means selling to another dentist, a small partnership, or a local group that is not part of a national chain: an associate stepping up to principal, a dentist relocating from another region, or a small group running two or three sites. Independent buyers usually pay less on a headline basis, because they cannot access the same cheap debt or centralised cost savings. In exchange, independent sales often complete faster, involve lighter due diligence, and give you more flexibility on terms such as a phased handover or a retained clinical role.
Valuation: How the Multiples Differ
The valuation method is the same regardless of buyer type. You normalise maintainable earnings (broadly adjusted EBITDA), apply a market multiple to arrive at goodwill, then add the tangible assets and, separately, the property if it is owned. Goodwill is typically 60 to 80 percent of the total price, with tangibles making up the balance. The multiple is where buyer type shows up.
Indicative 2026/27 goodwill multiples by practice profile are roughly:
- NHS-heavy, single-handed, lower-demand region: around 0.6 to 0.9 times maintainable earnings.
- Mixed, multi-surgery, normal-demand area: around 0.9 to 1.2 times.
- Private-focused, high-demand: around 1.1 to 1.4 times.
These are independent-buyer ranges; a corporate strategic premium can exceed the top of the relevant band where the group has a specific reason to want the practice. Treat all of these as ranges, never a single number, and never anchor on a buyer's opening offer. The gap between corporate and independent pricing tends to be widest for high-private practices, where future income is more predictable, and narrowest for small NHS-heavy practices, where a corporate may have little appetite at all.
Deal Structure: Share Sale or Asset Sale
Structure is where corporate and independent deals most often part company, and it drives the tax outcome more than the headline price does.
Corporate acquirers frequently prefer a share sale with part of the consideration deferred as an earn-out. You sell the shares in your company, and the trade, NHS contract, staff and liabilities transfer inside it. There is no contract novation, because the contract never leaves the company. For the seller, a share sale can be a clean route to Business Asset Disposal Relief, provided you have held at least 5 percent of the ordinary share capital and 5 percent of the voting rights, have been an officer or employee, and the company has been trading throughout the two years to disposal.
Independent buyers more often prefer an asset sale. The buyer purchases the goodwill, equipment and the benefit of the NHS contract directly, leaving you to wind up the selling entity. An asset sale needs the commissioner to consent to novating the NHS contract to the new owner, and some commissioners treat the sale as a trigger to revisit contract value. An asset sale by a company can also expose the proceeds to a double tax charge (corporation tax in the company, then a further charge on extracting the cash), which is one reason incorporated principals often favour a share exit.
We cover the full mechanics, including the company double-tax trap and how goodwill amortisation relief works for the buyer, in our asset sale versus share sale guide for dental practices.
Tax on the Sale: BADR and the 6 April 2026 Step
Both routes are capital disposals, so gains fall under Capital Gains Tax rather than income tax. The headline relief is Business Asset Disposal Relief (BADR), which applies a reduced CGT rate to qualifying gains up to a £1 million lifetime limit per individual. The rate is 14 percent for disposals up to 5 April 2026, then 18 percent from 6 April 2026. Gains above the lifetime limit are taxed at the main CGT rate.
The 6 April 2026 step matters for timing. The CGT date of disposal is the date of an unconditional contract, not completion. An unconditional exchange on or before 5 April 2026 fixes the 14 percent rate even if completion follows later. A conditional contract, for example one conditional on the commissioner consenting to an NHS contract novation, only disposes when the condition is satisfied, so it may miss the deadline. We work through how to time a disposal around this step in our guide to selling around the 2026 BADR rate rise.
Earn-Outs: Where Corporate Deals Get Complicated
This is the single biggest tax difference between the two routes, and it is widely misunderstood. An earn-out is the part of the price tied to future performance after you have sold. Corporate acquirers use them far more than independent buyers do, partly to bridge a valuation gap and partly to keep the selling principal motivated through a handover.
Where the earn-out is unascertainable at completion (its value genuinely depends on future events), the tax treatment follows the Marren v Ingles principle. The right to receive the future payment is itself a separate asset that you dispose of at completion. So you are charged CGT at completion on the valued right, and then charged again on a second disposal when the cash actually arrives. Two consequences matter:
- BADR generally does not reach the second disposal. The right to the earn-out is not itself a qualifying business asset, so the earn-out element is usually taxed at the main CGT rate, not the BADR rate. An earn-out can therefore push a meaningful slice of your consideration outside the relief band.
- A later shortfall can be carried back. If the cash you eventually receive is less than the valued right, that capital loss can be carried back against the original gain.
The crucial correction to a common myth: a genuine earn-out is capital, not income. It is not taxed at 40 or 45 percent income tax simply because it is contingent or deferred. The risk is not income treatment, it is that the earn-out falls outside BADR and so attracts the main CGT rate. Where the deferred amount is instead ascertainable (a fixed sum payable in instalments), the whole amount is taxed at completion, but instalment relief can spread the tax payment over up to eight years where the consideration is payable over more than 18 months. The detail of all this sits in our earn-outs and deferred consideration guide.
Timeline and Certainty
Corporate buyers run dedicated acquisitions teams and a standardised due diligence process covering financials, contracts, premises, equipment, staff and compliance. Completion typically takes four to eight months from first approach. Delays cluster where the practice has incomplete records, unresolved NHS contract issues, or a lease that needs renegotiating. The upside is process certainty: a corporate that has cleared its internal approvals rarely struggles to fund the deal.
Independent buyers are usually less formal. A sale to an associate who already knows the practice can complete in two to four months, with due diligence often limited to the accounts, the NHS contract and the lease. The risk runs the other way: an independent buyer, especially a first-time principal, may struggle to secure finance, and a chain that depends on their borrowing can fall through late.
Post-Sale Role and Restrictions
Corporate buyers typically want the selling principal to stay on for a transitional period, often around 6 to 12 months, as a salaried associate or clinical lead, to hold continuity for patients and staff. After that you are free to leave, but restrictive covenants are common: non-compete and non-solicitation clauses lasting a few years within a defined radius. Where the deal includes an earn-out, your post-sale performance is also financially tied to the practice for the earn-out period.
Independent buyers are usually more flexible. You might agree to work part-time for a few years or step away sooner, and restrictive covenants tend to be shorter and narrower, reflecting the smaller scale of the buyer. Some independent buyers are happy for you to continue as an unrestricted associate in the same chair.
NHS Contract Considerations
The NHS contract (a General Dental Services or Personal Dental Services agreement in England, with equivalents in Wales and Northern Ireland) is a central asset, and how it moves depends on structure. In a share sale the contract stays inside the company, so there is no novation. In an asset sale the contract transfers by novation, which requires commissioner consent, and that consent is not automatic. Some commissioners use the change of contractor as a trigger to renegotiate, and value reductions on novation are not unheard of.
Corporate buyers value contracts with stable UDA delivery and a clean performance history, and they have the systems to manage year-end reconciliation. Remember that under-delivery of 4 percent or less (delivering 96 to 100 percent of contracted activity) is carried forward into the next year rather than clawed back in cash, while delivering below 96 percent lets the commissioner recover the overpayment. A contract carrying clawback exposure is less attractive to any buyer, so clean it up before going to market.
Property: Owned or Leased?
If you own the premises you have a second asset to deal with, and the two buyer types tend to handle it differently. Corporate acquirers often want to buy the property as well, at a separate market value, which can lift total proceeds. The CGT treatment of the property depends on how it is held and how it has been used: relief on an associated property disposal is fact-sensitive and HMRC scrutinises it, so do not assume the goodwill relief position carries across to the building.
Independent buyers are more likely to lease the premises from you, leaving you with ongoing rental income. That can suit a phased exit, but it keeps you financially connected to the practice and may not fit a clean break. Rental income is taxed as property income, not as a capital gain, so model the two paths separately.
Which Route Suits Which Practice?
- High-private practices: corporate buyers often pay a premium here, because private income is more predictable. The valuation gap between corporate and independent is widest, so if maximum cash is the priority a corporate route is usually stronger, subject to the earn-out tax cost.
- NHS-heavy practices: corporates may still be interested, but the multiple sits lower in the range. A well-regarded local independent who can hold UDA delivery may match a corporate, and the gap is narrower.
- Small single-handed practices: corporates often pass, because the acquisition cost is high relative to the return. An independent sale to an associate or a local dentist is usually the realistic path.
- Multi-site groups: a corporate is the natural exit. Independent buyers rarely have the capital or management bandwidth to take on several sites at once.
Practical Steps Before You Decide
Get an independent professional valuation before approaching any buyer, and use it as your benchmark rather than a buyer's opening number. Our practice valuation service uses maintainable-earnings multiples and market comparables specific to your region and practice mix.
Review your NHS contract. Check the per-UDA value, the annual target and the clawback position, and use our NHS UDA value calculator to understand the contract's financial profile. A contract with a history of clawback weakens any sale.
Pin down your tax position early. BADR's two-year qualifying period and the earnings normalisation behind a credible valuation both need roughly 24 months of lead time, so the planning starts well before you go to market. Model the deal structure, not just the price: a higher headline offer loaded with an earn-out taxed at the main CGT rate can net less than a lower all-cash offer that sits inside BADR. Speak to a dental-specialist accountant before signing heads of terms.
Summary: Corporate vs Independent at a Glance
| Factor | Corporate acquirer | Independent buyer |
|---|---|---|
| Headline price | Often higher; strategic premium can exceed independent ranges | Usually within standard multiple ranges |
| Typical structure | Often a share sale, frequently with an earn-out | Often an asset sale, more often all cash |
| Earn-out tax | Earn-out usually outside BADR, taxed at main CGT rate | Less common; if all cash, full BADR if conditions met |
| NHS contract | Stays in the company on a share sale (no novation) | Novated on an asset sale, needs commissioner consent |
| Timeline | Around 4 to 8 months | Around 2 to 4 months |
| Due diligence | Extensive and standardised | Lighter, but finance risk on the buyer side |
| Post-sale role | Transitional period common, longer covenants | More flexible, shorter and narrower covenants |
| Property | Often bought outright at separate value | Often leased back to you |
The right path depends on your priorities. If maximum proceeds and process certainty matter most, a corporate sale is often stronger, as long as you have priced in the earn-out tax cost and accepted the structure. If you value flexibility, a faster process and a continuing connection to the practice, an independent sale may suit you better. Either way, the structure and the tax shape the real number, so get advice before you commit.
For a full assessment of your sale options, including tax modelling and a buyer comparison, see our dental accountancy services or book a free practice health check.